公开(公告)号：US20150250799A1

公开(公告)日：2015-09-10

申请号：US14716159

申请日：2015-05-19

申请人： Chao CHEN ,  Haibing DENG ,  Haibing Guo ,  Feng HE ,  Lei Jiang ,  Fang Liang ,  Yuan Mi ,  Huixin Wan ,  Yao-Chang Xu ,  Hongping Yu ,  Ji Yue Zhang

发明人： Chao CHEN ,  Haibing DENG ,  Haibing Guo ,  Feng HE ,  Lei Jiang ,  Fang Liang ,  Yuan Mi ,  Huixin Wan ,  Yao-Chang Xu ,  Hongping Yu ,  Ji Yue Zhang

IPC分类号： A61K31/551 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/4709

CPC分类号： A61K31/551 ,  A61K31/437 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/5513 ,  A61K45/06 ,  C07D471/04 ,  C07D491/107 ,  C07D519/00

摘要： The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

摘要翻译： 本发明涉及式（I）的化合物及其盐：其中取代基如说明书中所定义; 用于治疗人或动物体的式（I）化合物，特别是关于c-Met酪氨酸激酶介导的疾病或病症; 使用式（I）化合物制备用于治疗这些疾病的药物; 包含式（I）化合物，任选在组合配偶体存在下的药物组合物，以及制备式（I）化合物的方法。

公开(公告)号：US20130245002A1

公开(公告)日：2013-09-19

申请号：US13613291

申请日：2012-09-13

申请人： Chao CHEN ,  Haibing DENG ,  Haibing GUO ,  Feng HE ,  Lei JIANG ,  Fang LIANG ,  Yuan MI ,  Huixin WAN ,  Yao-Chang XU ,  Hongping YU ,  Ji Yue ZHANG

发明人： Chao CHEN ,  Haibing DENG ,  Haibing GUO ,  Feng HE ,  Lei JIANG ,  Fang LIANG ,  Yuan MI ,  Huixin WAN ,  Yao-Chang XU ,  Hongping YU ,  Ji Yue ZHANG

IPC分类号： C07D471/04 ,  A61K31/496 ,  A61K31/5513 ,  A61K31/5377 ,  C07D491/107 ,  A61K45/06 ,  A61K31/437

CPC分类号： A61K31/551 ,  A61K31/437 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/5513 ,  A61K45/06 ,  C07D471/04 ,  C07D491/107 ,  C07D519/00

摘要： The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).